कंपनी का अवलोकन
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology enterprise dedicated to identifying, developing, and commercializing therapies designed to address significant unmet medical needs within the United States healthcare landscape. The company operates specifically within the healthcare sector, focusing its industry activities on biotechnology, a field characterized by high innovation potential and substantial regulatory hurdles for drug candidates such as UNI 494. This pro-drug of Nicorandil is currently being developed as a targeted treatment for acute kidney injury, representing a specific therapeutic avenue within the broader biotech industry. The total market capitalization of the entity stands at $162.78M, while the organization employs a workforce of 21 individuals to execute its research and development pipeline.
वित्तीय स्वास्थ्य
The financial statements for Unicycive Therapeutics, Inc. reveal a net income of $-26,555,000 over the trailing twelve months, with an EBITDA of $-29,483,000 and revenue figures marked as unavailable in the current reporting period. The substantial gap between the reported revenue (N/A) and the significant negative net income highlights a cost structure typical of clinical-stage biotechnology firms where operating expenses are heavily weighted toward research, clinical trials, and regulatory compliance rather than sales and marketing. The company's free cash flow stands at $-22,924,500, which indicates a current consumption of cash reserves to fund operations and development activities rather than generating surplus liquidity. Regarding margins, the gross margin is recorded at 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, reflecting the pre-revenue or early-stage nature of the business where no gross profit is yet being realized from commercial sales. The balance sheet shows a cash position of $41.27M against total debt of $117,000, resulting in a debt-to-equity ratio of 0.39. This disparity between liquid assets and liabilities suggests a conservative balance sheet structure with minimal leverage relative to equity. Furthermore, the current ratio is 2.58, indicating that the company holds 2.58 times more current assets than current liabilities, which points to a robust short-term liquidity position capable of meeting immediate obligations. Finally, the return on equity is -141.1% and the return on assets is -45.7%, metrics that reveal management is currently operating in a loss-making environment where capital employed is generating negative returns due to the developmental stage of the drug candidates.
मूल्यांकन आकलन
The valuation metrics for Unicycive Therapeutics, Inc. show a P/E Ratio (TTM) as N/A due to negative earnings, while the forward P/E is calculated at 0.75, implying market expectations of future profitability or a valuation based on projected earnings that differ significantly from current trailing figures. The price-to-book ratio stands at 4.73, suggesting that the market is valuing the company at a significant premium over its book value, which often occurs with biotech firms holding valuable intellectual property and clinical pipelines. Since the price-to-sales ratio is N/A, the market relies on alternative valuation metrics such as the EV/EBITDA of -4.12 to assess value, though the negative figure reflects the company's lack of current earnings power. The stock's recent price action ranges between a 52-week high of $11.00 and a 52-week low of $3.71, with the current trading price situated within this volatility range. The beta value is recorded at 1.80, indicating that the stock exhibits price volatility that is significantly higher than the broader market, moving nearly twice as much as the market index during periods of fluctuation.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company is currently in a development phase where historical comparative growth rates are not yet applicable or disclosed. Because the earnings are negative and revenue is not yet commercialized, the company does not pay dividends; consequently, the dividend yield is N/A and the payout ratio is 0.0%. Instead of distributing income to shareholders, the company reinvests all available resources into advancing its drug candidates through clinical trials and securing regulatory approvals. The overall growth and income profile is defined by a focus on capital appreciation potential through the successful commercialization of its pipeline rather than current income generation or consistent revenue expansion.